LEXX

Lexaria Bioscience Corp

Add to Watchlist

Advanced Chart

0.830

-0.009(-1.073%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.850

Open

0.840

VWAP

0.83

Vol

117.40K

Mkt Cap

16.23M

Low

0.8181

Amount

97.83K

EV/EBITDA(TTM)

Total Shares

14.32M

11.40M

EV/OCF(TTM)

P/S(TTM)

23.22

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

50.00K

-71.26%

50.00K

-72.81%

137.00K

+63.1%

Estimates Revision

The market is revising No Change the revenue expectations for Lexaria Bioscience Corp. (LEXX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.19%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-20.19%

In Past 3 Month

1 Analyst Rating

502.41% Upside

Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

502.41% Upside

Current: 0.830

Low

5.00

Averages

5.00

High

5.00

502.41% Upside

Current: 0.830

Low

5.00

Averages

5.00

High

5.00

H.C. Wainwright

Yi Chen

Buy

downgrade

$5 -> $4

2025-07-29

Reason

H.C. Wainwright

Yi Chen

Price Target

$5 -> $4

2025-07-29

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Lexaria Bioscience to $4 from $5 and keeps a Buy rating on the shares after the company reported interim results from the Phase 1b GLP-1-H24-4 study currently underway in Australia. The firm says DehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.

H.C. Wainwright

Buy

downgrade

$7 -> $5

2025-07-01

Reason

H.C. Wainwright

Price Target

$7 -> $5

2025-07-01

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Lexaria Bioscience to $5 from $7 and keeps a Buy rating on the shares. In April, the company closed a registered direct offering for 2M common shares at $1 per share for gross proceeds of $2M, notes the analyst, who believes that the company will need to raise additional capital within the next 12 months to fund operations.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$10 → $7

2025-01-24

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10 → $7

2025-01-24

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2024-12-02

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2024-12-02

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2024-11-25

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2024-11-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lexaria Bioscience Corp (LEXX.O) is -1.41, compared to its 5-year average forward P/E of -3.16. For a more detailed relative valuation and DCF analysis to assess Lexaria Bioscience Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.16

Current PE

-1.41

Overvalued PE

-0.33

Undervalued PE

-5.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.72

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.18

Undervalued EV/EBITDA

-4.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

42.78

Current PS

59.63

Overvalued PS

69.79

Undervalued PS

15.77